In yesterday’s Wall Street session, Alaunos Therapeutics Inc (NASDAQ:TCRT) shares traded at $0.08, up 0.94% from the previous session.
2 analysts cover Alaunos Therapeutics Inc (NASDAQ:TCRT), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $7.50 and a low of $7.50, we find $7.50. Given the previous closing price of $0.07, this indicates a potential upside of 10614.29 percent. TCRT stock price is now -32.09% away from the 50-day moving average and -81.29% away from the 200-day moving average. The market capitalization of the company currently stands at $18.05M.
The stock has received a hold rating from 2 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $7.50 as their price target over the next twelve months.
In other news, Boyle Kevin S. Sr., Chief Executive Officer sold 68,014 shares of the company’s stock on Sep 01. The stock was sold for $9,542 at an average price of $0.14. Upon completion of the transaction, the Chief Executive Officer now directly owns 798,236 shares in the company, valued at $63858.88. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 29, Director Vieser Jaime bought 1,250,000 shares of the business’s stock. A total of $812,500 was incurred on buying the stock at an average price of $0.65. This leaves the insider owning 1,250,000 shares of the company worth $100000.0. Insiders disposed of 68,014 shares of company stock worth roughly $5441.12 over the past 1 year. A total of 4.71% of the company’s stock is owned by insiders.
On Wednesday morning Alaunos Therapeutics Inc (NASDAQ: TCRT) stock kicked off with the opening price of $0.0710. During the past 12 months, Alaunos Therapeutics Inc has had a low of $0.07 and a high of $1.09. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 2.75, and a quick ratio of 2.75. The fifty day moving average price for TCRT is $0.1094 and a two-hundred day moving average price translates $0.3976 for the stock.
The latest earnings results from Alaunos Therapeutics Inc (NASDAQ: TCRT) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.04, missing analysts’ expectations of -$0.03 by -0.01. This compares to -$0.04 EPS in the same period last year. The net profit margin was -243040.00% and return on equity was -158.46% for TCRT.
Alaunos Therapeutics Inc(TCRT) Company Profile
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.